US2008261888A1PendingUtilityA1
Antibodies to PDGF-D
Est. expiryNov 10, 2018(expired)· nominal 20-yr term from priority
C07K 16/22C07K 14/49C12Q 2600/158A61K 38/00C12Q 1/6886A61P 43/00
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
PDGF-D, a new member of the PDGF/VEGF family of growth factors, as well as the nucleotide sequence encoding it, methods for producing it, antibodies and other antagonists to it, transfected and transformed host cells expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications, including methods for stimulating growth of a connective tissue or healing a wound in a mammal, which methods comprise administering to the mammal an effective amount of PDGF-D polypeptides or polynucleotides encoding the PDGF-D polypeptides.
Claims
exact text as granted — not AI-modified1 - 31 . (canceled)
32 . A method for stimulating proliferation of a cell which expresses a PDGF-D receptor, comprising contacting said cell with a polypeptide comprising the amino acid sequence of SEQ ID NO: 25, in an amount sufficient to stimulate said proliferation.
33 . The method of claim 32 , wherein said polypeptide comprises SEQ ID NO: 8.
34 . The method of claim 32 , wherein said cell is a vascular endothelial cell, a lymphatic endothelial cell, a connective tissue cell, a myofibroblast, or a glial cell.
35 . The method of claim 32 , wherein said stimulation of a cell causes angiogenesis.
36 . The method of claim 32 , further comprising directly delivering said polypeptide to a site where proliferation of a cell is desired.
37 . The method of claim 35 , wherein said direct delivery comprises injection.Join the waitlist — get patent alerts
Track US2008261888A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.